Mobilisin cream - for musculoskeletal pain 40 g

Product Description

Cream

Composition:

Active ingredients per 100 g of cream: flufenamic acid (N-[alpha, alpha, alpha-trifluoro-m-tolyl]-anthranilic acid) 3 g, ethylene glycol monosalicylate (corresponding to salicylic acid 2 g) 2.64 g, glycosaminoglycan polysulfate (MW 20,000-30,000) 0.2 g. For the full list of excipients, see section 6.1.

Excipients

Per 100 g of cream: Mono-diglycerides of fatty acids; sodium salts of sulfonated fatty alcohols 10 g, triglycerides of vegetable fatty acids 6.25 g, myristic alcohol 3.75 g, aluminum magnesium silicate 1 g, hydrochloric acid 25% 0.24 g, sorbic acid 0.10 g, isopropanol 0.10 g, rosemary oil 0.06 g, lemon balm oil 0.05 g, purified water to 100 g.

Therapeutic indications

Symptomatic treatment of: Localized painful, inflammatory and degenerative conditions of the musculoskeletal and supporting system, muscles, tendons, ligaments, joints, spine, intervertebral discs and soft tissue; muscle tension, motor pain; lumbago, neck stiffness, neuralgia, sciatica.

Contraindications

Hypersensitivity to salicylates or to any of the excipients. Do not apply the cream to mucous membranes, burns, infections, or other skin conditions. Do not apply to infants and children.

Dosage

Unless otherwise prescribed by your doctor, apply a 5-10 cm line of cream several times a day and massage gently. To achieve optimal therapeutic results, use Mobilisin regularly during treatment, if necessary even for a prolonged period.

Warnings and precautions

Wash your hands thoroughly after applying the cream. With chronic use, skin reactions may occur (see 4.8 "Undesirable effects"). Avoid intense exposure of the treated areas to sunlight. Avoid chronic use or application to large areas of skin in cases of kidney disease, particularly in cases of renal insufficiency. Prolonged application of MOBILISIN cream to large areas of skin may increase systemic absorption and requires caution (risk of salicylism, especially in patients with renal insufficiency). Use of topical products, especially if prolonged, may give rise to sensitization phenomena. In this case, it is necessary to discontinue treatment and initiate appropriate therapy.

Interactions

Chronic use of MOBILISIN cream on large areas of skin may increase systemic absorption and requires caution (risk of salicylism, especially in patients with renal insufficiency). determine an increase in the toxicity of methotrexate and the hypoglycaemic effect of sulfonylureas.

Undesirable effects

Skin and subcutaneous tissue disorders As with all products applied to the skin, it is possible that any of the components of MOBILISIN cream may cause an allergic reaction. Rare: Hypersensitivity reactions may occur in the form of skin irritation or erythema. Itching, rashes, and photosensitivity reactions may occur. These symptoms usually resolve upon discontinuation of treatment, which is indicated in such cases. Gastrointestinal disorders/general conditions: If MOBILISIN cream has been applied to large areas for a long period of time, side effects affecting one organ or the entire system may occur, as has also been observed following the systemic administration of medicines containing flufenamic acid and salicylic acid (including gastrointestinal symptoms, nausea, headache, dizziness, and general malaise). The doctor should take these symptoms into consideration and discontinue treatment if they persist.

Pregnancy and breastfeeding

The product should be used only when strictly necessary, under the direct supervision of a doctor, and for short periods of treatment only.